Sustained release of antiinfectives

Abstract

Provided, among other things, is a method of treating or ameliorating pulmonary infection in a cystic fibrosis patient comprising pulmonary administration of an effective amount of a liposomal/complexed antiinfective to the patient, wherein the (i) administrated amount is 50% or less of the comparative free drug amount, or (ii) the dosing is once a day or less, or (iii) both.

What is claimed: 
     
         1 . A liposomal ciprofloxacin formulation comprising ciprofloxacin encapsulated in a liposome, wherein the lipid component of the liposomes comprises cholesterol and a phosphatidylcholine, and the lipid component to ciprofloxacin weight ratio is less than 2.5:1 by weight. 
     
     
         2 . The liposomal ciprofloxacin formulation of  claim 1 , wherein the liposomes are unilamellar. 
     
     
         3 . The liposomal ciprofloxacin formulation of  claim 1 , wherein the phosphatidylcholine is hydrogenated soy phosphatidylcholine (HSPC). 
     
     
         4 . The liposomal ciprofloxacin formulation of  claim 2 , wherein the phosphatidylcholine is hydrogenated soy phosphatidylcholine (HSPC). 
     
     
         5 . A method of treating a  Pseudomonas aeruginosa  infection or an infection due to  P. aeruginosa  in the lungs of a patient in need thereof, comprising administering to the lungs of the patient an effective amount of a liposomal ciprofloxacin formulation which comprises ciprofloxacin encapsulated in a liposome, wherein the lipid component of the liposomes comprises cholesterol and a phosphatidylcholine, and the lipid component to ciprofloxacin weight ratio is less than 2.5:1 by weight. 
     
     
         6 . The method of  claim 5 , wherein the phosphatidylcholine is hydrogenated soy phosphatidylcholine (HSPC). 
     
     
         7 . The method of  claim 5 , wherein the liposomes are unilamellar. 
     
     
         8 . The method of  claim 5 , wherein the formulation is administered via inhalation. 
     
     
         9 . The method of  claim 6 , wherein the liposomes are unilamellar. 
     
     
         10 . The method of  claim 6 , wherein the formulation is administered via inhalation. 
     
     
         10 . The method of  claim 7 , wherein the formulation is administered via inhalation.